Therapeutics for diabetic complications
    41.
    发明授权
    Therapeutics for diabetic complications 有权
    糖尿病并发症治疗

    公开(公告)号:US06218411B1

    公开(公告)日:2001-04-17

    申请号:US09485297

    申请日:2000-02-08

    申请人: Hiroshi Koga

    发明人: Hiroshi Koga

    IPC分类号: A61K3144

    摘要: An agent for treating or ameliorating diabetic complications which contains at least one potassium channel activator as an active ingredient. The drug is expected to show a therapeutic or ameliorating action on diabetic complications such as retinopathy, neuropathy, nephropathy, peripheral circulation disorders, and skin ulcerations; it also proves effective in preventing, ameliorating, alleviating and gaining recovery from various symptoms and abnormalities caused by those diseases, as exemplified by blindness, proteinurea, pain, numbness, psychroesthesia, intermittent claudication and gangrene.

    摘要翻译: 用于治疗或改善含有至少一种钾通道活化剂作为活性成分的糖尿病并发症的药剂。 该药物预期对糖尿病并发症如视网膜病,神经病,肾病,外周循环障碍和皮肤溃疡显示出治疗或改善作用; 也证明有效预防,改善,缓解和恢复各种由这些疾病引起的症状和异常,例如失明,蛋白尿,疼痛,麻木,精神病,间歇性跛行和坏疽。

    N-(2-cyanoethyl)-6-fluoroalkyl-2h-1-benzopyran derivatives
    42.
    发明授权
    N-(2-cyanoethyl)-6-fluoroalkyl-2h-1-benzopyran derivatives 失效
    N-(2-氰基乙基)-6-氟烷基-2h -1-苯并吡喃衍生物

    公开(公告)号:US5646310A

    公开(公告)日:1997-07-08

    申请号:US448576

    申请日:1995-06-07

    IPC分类号: C07D311/58 A61K31/35

    CPC分类号: C07D311/58

    摘要: Described herein are benzopyran derivatives represented by the formula: ##STR1## wherein R, X and Y represent any of the following combinations:______________________________________ R X Y ______________________________________ C.sub.2 F.sub.5 O H C.sub.2 F.sub.5 S H CF.sub.3 S F C.sub.2 F.sub.5 S F C.sub.3 F.sub.7 S F ______________________________________ and pharmaceutically acceptable salts thereof. These compounds have an excellent potassium channel activity and are also excellent from the aspect of safety.

    摘要翻译: PCT No.PCT / JP94 / 00682 Sec。 371日期:1995年6月7日 102(e)日期1995年6月7日PCT 1994年4月25日PCT PCT。 第WO94 / 25021号公报 日期:1994年11月10日描述的是下式表示的苯并吡喃衍生物:其中R,X和Y表示以下组合中的任何一种: - RXY - C2F5 OH - C2F5 SH - CF3 SF - C2F5 SF - C3F7 SF-及其药学上可接受的盐。 这些化合物具有优异的钾通道活性,并且从安全性方面也是优异的。

    Benzopyran derivatives
    43.
    发明授权
    Benzopyran derivatives 失效
    苯并吡喃衍生物

    公开(公告)号:US5614633A

    公开(公告)日:1997-03-25

    申请号:US387745

    申请日:1995-02-17

    摘要: Novel benzopyran and benzoxazine derivatives represented by the general formula: ##STR1## wherein R.sub.1 and R.sub.2 represent a lower haloalkyl group, R.sub.3 represents a hydrogen atom, etc., R.sub.4 represents a heterocyclic group or A--O-- wherein A represents a cyclic structure, etc., R.sub.5 and R.sub.6 represent a lower haloalkyl, X represents .dbd.N--, N.fwdarw.O, etc, are disclosed. These compounds exhibit K.sup.+ channel opening activating and can be widely used as an anti-asthma drug, an anti-epilepsy drug, etc.

    摘要翻译: PCT No.PCT / JP93 / 01150 Sec。 371日期:1995年2月17日 102(e)日期1995年2月17日PCT 1995年3月15日PCT公布。 第WO94 / 04521号公报 日期1993年3月3日由以下通式表示的新型苯并吡喃和苯并恶嗪衍生物:其中R1和R2表示低级卤代烷基,R3表示氢原子等,R4表示杂环基或AO-,其中A表示 环状结构等,R5和R6表示低级卤代烷基,X表示= N-,N-→O等。 这些化合物显示K +通道开启活化,可广泛用作抗哮喘药,抗癫痫药等。

    Xanthone derivatives and process for producing the same
    45.
    发明授权
    Xanthone derivatives and process for producing the same 失效
    呫吨衍生物及其制备方法

    公开(公告)号:US4816479A

    公开(公告)日:1989-03-28

    申请号:US937101

    申请日:1986-12-02

    摘要: Xanthone derivatives of the formula (I): ##STR1## wherein W, X, Y and Z which may be the same or different represent a hydrogen atom, a halogen atom or a lower alkyl group having 1 to 4 carbon atoms; A is a hydrogen atom B is a hydroxymethyl group, a lower alkoxycarbonyl group having 1 to 4 carbon atoms, or a carboxyl group, provided that a --O--CH.sub.2 --B group is bonded to the 2- or 3-position of the xanthone ring and that there is no case in which X, Y, and Z are each a hydrogen atom concurrently; as well as intoxic salts thereof when B is a carboxyl group, and a process for preparing the same are disclosed.The compounds of formula (I) in accordance with the present invention are useful as diuretics having uricosuric activity and can be used in the treatment of edema or hypertension.

    Furobenzisoxazole derivatives
    46.
    发明授权
    Furobenzisoxazole derivatives 失效
    呋喃苯并恶唑衍生物

    公开(公告)号:US4791209A

    公开(公告)日:1988-12-13

    申请号:US860210

    申请日:1986-05-06

    IPC分类号: C07D498/04 A61K31/42

    CPC分类号: C07D498/04

    摘要: Novel furobenzisoxazole derivatives of the formula (I): ##STR1## (wherein R.sub.1, R.sub.2, R.sub.3 and R.sub.4 which may be the same or different represent a hydrogen atom, a halogen atom, or a lower alkyl group having 1-4 carbon atoms; R.sub.5 is a hydroxymethyl group, a carboxyl group or a lower alkoxy carbonyl group having 1-3 carbon atoms; and X is a sulfur atom or a --CH.dbd.CH-- group), as well as intoxic salts thereof when R.sub.5 is a carboxyl group, and process for preparing the same are disclosed.The derivatives of formula (I) and nontoxic salts thereof have hypotensive, uricosuric and diuretic activities and hence ae useful as therapeutics for treating hyperuricemia, edema and hypertension.

    摘要翻译: 式(I)的新型呋喃苯并异恶唑衍生物:其中R 1,R 2,R 3和R 4可以相同或不同,表示氢原子,卤素原子或具有1-4个碳原子的低级烷基 碳原子; R5是羟基甲基,羧基或具有1-3个碳原子的低级烷氧基羰基; X是硫原子或-CH = CH-基团),以及当其为R5时的中性盐 羧基,及其制备方法。 式(I)的衍生物及其无毒盐具有降血压,尿酸和利尿活性,因此可用作治疗高尿酸血症,水肿和高血压的治疗剂。